Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Virtus Pharmaceuticals Inc. Announces Launch of Prometrium (Progesterone, USP Capsules)

Written by: | admin@medadnews.com | Dated: Monday, August 1st, 2016

 

Tampa, FL, August 1 st , 2016 /Businesswire/ — Virtus Pharmaceuticals, Inc., a specialty niche pharmaceutical company, and part of the Linden Capital Partners (“Linden”) portfolio, today announced it has launched Prometrium® (Progesterone, USP Capsules). This is Virtus’ first branded product. Prometrium® complements an already strong product portfolio of products, which includes a focus on Women’s Health.

“With the launch of Prometrium®, we are now going beyond being a standard provider of generic products” commented Tina Guilder, CEO of the Company. “This is our first branded product launch and we hope to offer more mature brands to support our vision to provide affordable medicines that help secure long-term access to healthcare for people around the world”.

 

About Virtus Pharmaceuticals, Inc.
Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches and outstanding customer service. For more information, please visit the Company’s Web site at www.virtusrx.com

 

About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life sciences industries. Linden’s strategy is based upon three elements: (i) healthcare and life science industry specialization, (ii) integrated private equity and operating expertise, and (iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare.

 

Company Contact:
Tina Guilder
CEO
(813) 283-1344
www.virtusrx.com

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom